JMPWA
BCRX icon

JP Morgan Private Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$217K Buy
30,603
+1,309
+4% +$9.4K ﹤0.01% 1607
2023
Q2 		$206K Buy
29,294
+17,457
+147% +$140K ﹤0.01% 1380
2023
Q1 		$98.7K Buy
+11,837
New +$114K ﹤0.01% 1899

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

JP Morgan Private Wealth Advisors's BCRX Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 4.5% in Q3 2023, buying an estimated $9.4K and bringing the position to 30,603 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

JP Morgan Private Wealth Advisors first reported a position in BCRX in Q1 2023 and has held it in 3 quarters since. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 30,603 shares of BioCryst Pharmaceuticals worth $217K as of Q3 2023.
  • JP Morgan Private Wealth Advisors bought 1,309 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $9.4K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1607 holding.
  • JP Morgan Private Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2023 and has held it in 3 quarters since.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.